+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Selective Catechol-O-Methyltransferase Inhibitor Market by Indication, Product Type, Treatment Line, Distribution Channel, End User, Formulation, Molecular Type - Global Forecast to 2030- Product Image
Selective Catechol-O-Methyltransferase Inhibitor Market by Indication, Product Type, Treatment Line, Distribution Channel, End User, Formulation, Molecular Type - Global Forecast to 2030- Product Image
Sale

Selective Catechol-O-Methyltransferase Inhibitor Market by Indication, Product Type, Treatment Line, Distribution Channel, End User, Formulation, Molecular Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082016
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The selective COMT inhibitor market is experiencing significant transformation as clinical innovation, evolving reimbursement dynamics, and increased demand for advanced Parkinson’s therapies reshape the competitive landscape. Equipped with distinct molecular approaches and adaptive distribution strategies, market players are navigating a period of rapid regulatory, commercial, and technological change.

Market Snapshot: Selective COMT Inhibitors

Global demand for selective catechol-O-methyltransferase (COMT) inhibitors is rising steadily, driven by the escalation of Parkinson’s disease incidence and the call for therapies that extend levodopa efficacy. The market benefits from advances in both nitrocatechol and non-nitrocatechol design, with leading pharmaceutical innovators continuously refining formulations to reduce motor fluctuations and adverse effects. Regional diversity in healthcare infrastructure, payer policies, and patient demographics informs evolving market strategies, as initiatives increasingly focus on greater accessibility and precise treatment optimization.

Scope & Segmentation

This comprehensive report delivers in-depth segmentation and coverage of the selective COMT inhibitor market, incorporating product, clinical, and regional perspectives to support strategic decision-making.

  • Indication: Off Episodes; Parkinson’s Disease
  • Product Type: Combination Therapy (including Dopamine Agonist and Levodopa combinations); Single Agent
  • Treatment Line: First Line; Second Line; Third Line
  • Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
  • End User: Clinics; Home Care; Hospitals
  • Formulation: Capsules; Dispersible Tablets; Oral Tablets
  • Molecular Type: Nitrocatechol; Non-Nitrocatechol
  • Geography: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (United Kingdom, Germany, France, multiple others); Asia-Pacific (China, India, Japan, and more key markets)
  • Key Competitors: Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Dr. Reddy's Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals PLC

Key Takeaways

  • Selective COMT inhibitors are driving a paradigm shift in Parkinson’s management by targeting both symptom relief and long-term outcomes, expanding options for treatment optimization across patient profiles.
  • The pipeline favors molecules distinguished by advanced pharmacokinetic profiles, allowing for improved central nervous system penetration and differentiated safety futures.
  • Industry alliances and licensing agreements are accelerating the development and broader market entry of next-generation molecules, rapidly updating portfolio strategies for established and emerging firms.
  • Growth in digital health platforms is enhancing adherence and supporting real-world evidence collection, equipping payers and providers with data to inform value-based reimbursement decisions.
  • Regional variances in healthcare infrastructure and regulatory oversight are compelling market entrants to tailor strategies, particularly regarding pricing, access, and product differentiation in regions such as Asia-Pacific and EMEA.

Tariff Impact: The 2025 Landscape

The 2025 tariff framework has introduced new challenges and strategic inflection points. Increased import duties on pharmaceutical ingredients and finished products are impacting production costs, particularly for manufacturers with international supply chains. Companies are responding by localizing synthesis, negotiating patient assistance initiatives, and leveraging joint ventures to preserve commercial viability and market access amid fluctuating costs. These tariff-induced dynamics underscore the necessity of supply chain flexibility and active stakeholder engagement in maintaining access to selective COMT therapies.

Methodology & Data Sources

Our research combines in-depth interviews with biopharmaceutical executives, clinicians, and key thought leaders, supported by secondary analysis of peer-reviewed publications, clinical trial databases, regulatory files, and proprietary pharmaceutical datasets. Data triangulation and expert validation underpin robust, actionable insights that reflect current market realities and strategic priorities.

Why This Report Matters

  • Enables senior decision-makers to benchmark market positioning against emerging scientific, regulatory, and competitive dynamics.
  • Supplies actionable guidelines for optimizing product portfolios and commercial strategies in complex, evolving therapy landscapes.
  • Equips leadership to anticipate and address regional access barriers, pricing pressures, and disruptive technology adoption with data-driven foresight.

Conclusion

With advances in selective COMT inhibition poised to redefine Parkinson’s treatment paradigms, this report presents essential insight for industry leaders navigating complexity and pursuing growth. Strategic adaptability and targeted innovation remain central to securing a leading market position.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Selective Catechol-O-Methyltransferase Inhibitor Market, by Indication
8.1. Introduction
8.2. Off Episodes
8.3. Parkinson's Disease
9. Selective Catechol-O-Methyltransferase Inhibitor Market, by Product Type
9.1. Introduction
9.2. Combination Therapy
9.2.1. Dopamine Agonist Combination
9.2.2. Levodopa Combination
9.3. Single Agent
10. Selective Catechol-O-Methyltransferase Inhibitor Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Selective Catechol-O-Methyltransferase Inhibitor Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Selective Catechol-O-Methyltransferase Inhibitor Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Selective Catechol-O-Methyltransferase Inhibitor Market, by Formulation
13.1. Introduction
13.2. Capsules
13.3. Dispersible Tablets
13.4. Oral Tablets
14. Selective Catechol-O-Methyltransferase Inhibitor Market, by Molecular Type
14.1. Introduction
14.2. Nitrocatechol
14.3. Non Nitrocatechol
15. Americas Selective Catechol-O-Methyltransferase Inhibitor Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Selective Catechol-O-Methyltransferase Inhibitor Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Selective Catechol-O-Methyltransferase Inhibitor Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Sun Pharmaceutical Industries Ltd.
18.3.3. Teva Pharmaceutical Industries Ltd.
18.3.4. Viatris Inc.
18.3.5. Dr. Reddy's Laboratories Ltd.
18.3.6. Lupin Limited
18.3.7. Hikma Pharmaceuticals PLC
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET MULTI-CURRENCY
FIGURE 2. SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET MULTI-LANGUAGE
FIGURE 3. SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY OFF EPISODES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DOPAMINE AGONIST COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY LEVODOPA COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY SINGLE AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISPERSIBLE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY NITROCATECHOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY NON NITROCATECHOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 55. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 56. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 104. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 109. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 112. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 113. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 125. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 128. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 129. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 133. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 136. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 165. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 168. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 181. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 184. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 185. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 189. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 192. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 213. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 216. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 224. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 237. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 240. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 245. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 248. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 249. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC SELECTIVE CATECHOL-O-METHYLTRANSFERASE INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC SELEC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Selective Catechol-O-Methyltransferase Inhibitor market report include:
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Hikma Pharmaceuticals PLC

Related Topics

Related Reports

Catechol-O-methyltransferase (COMT) Inhibitor - Pipeline Insight, 2025 - Product Image

Catechol-O-methyltransferase (COMT) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
DNA Methyltransferase Inhibitor - Pipeline Insight, 2025 - Product Image

DNA Methyltransferase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Siderophore and Related Natural Products Biosynthesis. Methods in Enzymology Volume 702 - Product Image

Siderophore and Related Natural Products Biosynthesis. Methods in Enzymology Volume 702

  • Book
Modifications and Targeting of Protein Termini Part A. Methods in Enzymology Volume 684 - Product Image

Modifications and Targeting of Protein Termini Part A. Methods in Enzymology Volume 684

  • Book
Drug Discovery Enzymes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Drug Discovery Enzymes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 136 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.